Search | IOVS | ARVO Journals

Showing 1 – 19 of 19

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

AAV8- hLCA5 Subretinal Delivery to the Macula in LCA5 -associated Leber Congenital Amaurosis ( LCA5 -LCA): Preliminary Safety and Efficacy Results of an Ongoing Phase I/II Gene Therapy Trial

Tomas S Aleman; Artur V Cideciyan; Mariejel L Weber; Arlene Santos; Katherine E. Uyhazi; Kelsey Parchinski; William Chung; Paris Margaritis; junwei sun; Drew Scoles; Alexandra V Garafalo; Ashwath Jayagopal; Benjamin R Yerxa; Sarah Tuller; Albert Maguire; Jean Bennett

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3288.

ARVO Annual Meeting Abstract June 2024

Development of OPGx-BEST1 AAV gene therapy for the treatment of bestrophinopathies

Mayur Choudhary; Alexa Gray; Yu Sato; Jennifer Caroline Kwok; Vik Arora; Benjamin R Yerxa; Artur V Cideciyan; Gustavo D Aguirre; William A Beltran; Ashwath Jayagopal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5335.

ARVO Annual Meeting Abstract June 2017

In vitro and In vivo Sustained Release of Dexamethasone from Intravitreal Implants

Janet Tully; Mari Yang; Stuart Williams; Sanjib Das; Rozemarijn S Verhoeven; RiLee Robeson; Rhett M Schiffman; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4111.

ARVO Annual Meeting Abstract June 2017

Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants

Gary Owens; Melissa Sandahl; Janet Tully; Jennifer Haley; Kwadwo Caesar; Stuart Williams; Rozemarijn S Verhoeven; Andres Garcia; Tomas Navratil; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):409.

ARVO Annual Meeting Abstract June 2017

A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

RiLee Robeson; Rozemarijn S Verhoeven; Andres Garcia; Sanjib Das; Kristie Hamby; Melissa Hernandez; Glenwood G Gum; Benjamin R Yerxa; Tomas Navratil

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1072.

ARVO Annual Meeting Abstract June 2017

Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy

Tomas Navratil; Jinny Conley; Rozemarijn S Verhoeven; Kristin Blackwell; Akshay Nadkarni; Leo Trevino; Benjamin R Yerxa; Michael Depenbusch; Tracey Knox; Iqbal Ahmad; Thomas R Walters; Steven L Mansberger

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2108.

ARVO Annual Meeting Abstract June 2017

Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

Steven L Mansberger; Jinny Conley; Rozemarijn S Verhoeven; Kristin Blackwell; Michael Depenbusch; Tracey Knox; Thomas R Walters; Iqbal Ahmad; Benjamin R Yerxa; Tomas Navratil

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2110.

ARVO Annual Meeting Abstract June 2017

Nonclinical Development of An Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema

Stuart Williams; Rozemarijn S Verhoeven; Dustin Melton; Janet Tully; Sanjib Das; RiLee Robeson; Andres Garcia; Mari Yang; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4457.

ARVO Annual Meeting Abstract June 2017

In vitro Sustained Release of Tyrosine Kinase Inhibitors from Biodegradable PRINT Implants

Melissa Sandahl; Kwadwo Caesar; Janet Tully; Mari Yang; Stuart Williams; Rhett M Schiffman; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4458.

ARVO Annual Meeting Abstract June 2015

Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

Tomas Navratil; Andres Garcia; Rozemarijn S Verhoeven; Leo Trevino; Brian C Gilger; Steven L Mansberger; Donald L Budenz; Iqbal Ike K. Ahmed; Richard A. Lewis; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5706.

ARVO Annual Meeting Abstract April 2014

Bioerodable Hydrophobic Intravitreal Implants for the Extended Release of Bevacizumab for Age Related Macular Degeneration

John Savage; Kevin Patrick Herlihy; Gary Owens; Jeremy Hansen; RiLee Robeson; Benjamin Maynor; Tomas Navratil; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1951.

ARVO Annual Meeting Abstract April 2014

Extended Release of Microfabricated Protein Particles from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration

Kevin Patrick Herlihy; Stuart Williams; Gary Owens; John Savage; Lindsay Gardner; RiLee Robeson; Benjamin Maynor; Tomas Navratil; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1960.

ARVO Annual Meeting Abstract April 2014

Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action

Tomas Navratil; Andres Garcia; Janet Tully; Benjamin Maynor; Iqbal Ike K Ahmed; Donald L Budenz; Richard A Lewis; Steven L Mansberger; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3548.

ARVO Annual Meeting Abstract April 2014

Photocurable Hydrogel Implants for the Extended Release of Bevacizumab for the Treatment of Age Related Macular Degeneration

Stuart Williams; Kevin Herlihy; Gary Owens; John Savage; Lindsay Gardner; Janet Tully; Benjamin Maynor; Tomas Navratil; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):471.

ARVO Annual Meeting Abstract April 2014

Controlled and Extended Release of Difluprednate from Biodegradable Intraocular Implants Engineered using PRINT® Technology

Ayush Verma; Jeff Kindig; Kyle Sebastian; Janet Tully; Andres Garcia; RiLee Robeson; Benjamin Maynor; Tomas Navratil; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):476.

ARVO Annual Meeting Abstract April 2014

Precisely Engineered Biodegradable Drug Delivery Systems for the Extended Release of Prostaglandin Analogues in the Anterior Chamber

Andres Garcia; Janet Tully; Sanjib Das; Tyler Pegoraro; Leo Trevino; Benjamin Maynor; Tomas Navratil; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5268.

ARVO Annual Meeting Abstract April 2014

Development of Precisely-Engineered Biodegradable Drug Delivery Systems for Posterior Ocular Drug Delivery: PRINT® PLGA Extended Release Implants for anti-VEGF Biologics

Benjamin Maynor; Andres Garcia; Janet Tully; Gary Owens; RiLee Robeson; Tomas Navratil; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5269.

ARVO Annual Meeting Abstract April 2014

Intracameral Conversion of Travoprost to Travoprost Acid in the Normotensive Beagle Dog Model

Leo Trevino; Tomas Navratil; RiLee Robeson; Andres Garcia; Janet Tully; Michael Hunter; Daria Stoltz; Benjamin Maynor; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5270.

Retinal Cell Biology November 2002

The P2Y 2 Receptor Agonist INS37217 Stimulates RPE Fluid Transport In Vitro and Retinal Reattachment in Rat

PDF

Arvydas Maminishkis; Stephen Jalickee; Sasha A. Blaug; Jodi Rymer; Benjamin R. Yerxa; Ward M. Peterson; Sheldon S. Miller
TAGS: agonists, bathing, blister, detached retina repairs, fluid transport, tissue membrane, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid, cattle, eye, body tissue
Invest. Ophthalmol. Vis. Sci.. 2002; 43(11):3555-3566.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

AAV8- hLCA5 Subretinal Delivery to the Macula in LCA5 -associated Leber Congenital Amaurosis ( LCA5 -LCA): Preliminary Safety and Efficacy Results of an Ongoing Phase I/II Gene Therapy Trial

Development of OPGx-BEST1 AAV gene therapy for the treatment of bestrophinopathies

In vitro and In vivo Sustained Release of Dexamethasone from Intravitreal Implants

Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants

A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy

Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

Nonclinical Development of An Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema

In vitro Sustained Release of Tyrosine Kinase Inhibitors from Biodegradable PRINT Implants

Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

Bioerodable Hydrophobic Intravitreal Implants for the Extended Release of Bevacizumab for Age Related Macular Degeneration

Extended Release of Microfabricated Protein Particles from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration

Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action

Photocurable Hydrogel Implants for the Extended Release of Bevacizumab for the Treatment of Age Related Macular Degeneration

Controlled and Extended Release of Difluprednate from Biodegradable Intraocular Implants Engineered using PRINT® Technology

Precisely Engineered Biodegradable Drug Delivery Systems for the Extended Release of Prostaglandin Analogues in the Anterior Chamber

Development of Precisely-Engineered Biodegradable Drug Delivery Systems for Posterior Ocular Drug Delivery: PRINT® PLGA Extended Release Implants for anti-VEGF Biologics

Intracameral Conversion of Travoprost to Travoprost Acid in the Normotensive Beagle Dog Model

The P2Y 2 Receptor Agonist INS37217 Stimulates RPE Fluid Transport In Vitro and Retinal Reattachment in Rat

To View More...

You must be signed into an individual account to use this feature.